microbiota transplantation
Pilar Manrique Ronquillo, Research Scientist at Microviable Therapeuthics, talks about the donor-based microbiome therapeutic products research and development.
The findings of a recent study suggest that FMT is an effective strategy to mitigate the intestinal side effects of cancer immunotherapy.
Lihi Godny, from Rabin Medical Center in Israel, talks about the next steps research has to focus in to improve the FMT efficacy for IBD patients.
The findings of a recent study suggest that the gut microbiota contributes to improve metabolic health after gastric bypass surgery.
Clara Desvignes, Head of Microbiome at VCLS, spoke about the continuously evolving regulatory landscape on Fecal Microbiome Transplant.
Researchers found that the microbiota of the recipient, rather than that of the donor, determines the microbial mix resulting from a fecal transplant.
The findings of a new research could help to optimize fecal microbiota transplantation (FMT) protocols and identify the most suitable donors for transplantation.
Faecal microbiota transplant appears to effectively improve both clinical parameters and bacterial balance in the liver, especially in thin individuals.
Sam Costello (The Queen Elizabeth Hospital in Adelaide) presented recent evidences about FMT and IBDs.
Maria Teresa Abreu (University of Miami, USA) discussed some new strategies to design clinical trials.
